Kexing Biopharm signed a Drug Cooperation Agreement with Haichang Biotech to obtain the commercial license of HC007 (a complex preparation for injection, a generic drug of a broad-spectrum anticancer drug) in all regions except the US.

The company was approved to set up the Shenzhen postdoctoral innovation practice base.

The company successfully landed on the A-share technology innovation board with the stock code of 688136, becoming the leader of high quality biologicals.

Our technology center was ratified as the Guangdong Gene Engineering Recombinant Protein Therapeutics Engineering Technology Center.

Our technology center was ratified as the Shandong Protein Therapeutics Engineering Laboratory.

The company was restructured into Kexing Biopharmaceutical Co., Ltd. (Kexing Biopharm).

We launched the slogan Precise Products, Predictable Effects, Health Protection and the new logo.

Shandong Kexing Bioproducts Co., Ltd. was established as an industrial platform for recombinant human erythropoietin.

Our technology center was ratified as the Shandong Provincial Enterprise-level Technology Center.

We integrated the traditional Chinese medicine business focusing on KEHUANG CAPSULE around hepatopathy treatment.

The EPO agent not containing albumin obtained the certificate of invention patent (patent No. ZL200610146206.0).

Combined Clostridium Butyricum and Bifidobacterium Powder/Capsule, Live (CLOBICO) was officially approved for production.

Human Granulocyte Colony-stimulating Factor Injection (WHITE-C) was officially approved for production.

Shenzhen Kexing was recognized by the Ministry of Science and Technology as the Industrialization Base of National 863 Plan Achievement.

Human Erythropoietin Injection (CHO Cell) (EPOSINO) was officially approved for production as Class II biological products.

Shandong Kexing Bioproducts Co., Ltd. was established as an industrial platform for recombinant human erythropoietin.